{"id":24566,"date":"2022-03-30T08:43:21","date_gmt":"2022-03-30T14:43:21","guid":{"rendered":"https:\/\/saluddigital.com\/?p=24566"},"modified":"2025-10-21T09:44:04","modified_gmt":"2025-10-21T15:44:04","slug":"fda-aprueba-sistema-de-monitoreo-remoto-para-pacientes-con-enfermedades-cardiovasculares","status":"publish","type":"post","link":"https:\/\/saluddigital.com\/en\/big-data\/fda-aprueba-sistema-de-monitoreo-remoto-para-pacientes-con-enfermedades-cardiovasculares\/","title":{"rendered":"FDA Approves Remote Monitoring System for Cardiovascular Disease Patients"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The US Food and Drug Administration (FDA) has approved an expanded indication for Abbott's CardioMEMS remote monitoring system. <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In February, the pharmaceutical company Abbott announced that the FDA had granted approval to the CardioMEMS system, which aims to support the care of people living with heart failure. This system consists of a sensor that alerts doctors early about the patient's health condition and the possibility that heart failure will worsen.<\/p>

Abbott explained in a statement that more than 6.2 million Americans live with heart failure, a number that will double by 2030. In this sense, remote monitoring systems can improve patient care and make specialists act more efficiently. quickly to avoid complications.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The CardioMEMS sensor is a clip-sized device that, once placed in the pulmonary artery during a minimally invasive procedure, monitors pressure changes that indicate worsening heart failure.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In this way, the sensor is able to wirelessly transmit information on daily pressure readings to the patient's clinical team, allowing doctors to make changes in therapy to control the progression of the disease to a later and more serious stage. Similarly, the system allows patients to take control of their disease from wherever they are.<\/p>

In addition, this type of remote monitoring system has been shown in clinical trials to be able to reduce hospitalizations of patients in advanced stages of heart disease. In fact, the CardioMEMS system was subjected to a clinical trial in which 3,600 patients participated. "CardioMEMS demonstrated a significant 19 % reduction in the study's composite endpoint and a 28 % reduction in hospitalizations for heart failure," explains Abbott.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t BIBLIOGRAPHY<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

ABBOTT<\/strong><\/p>

https:\/\/abbott.mediaroom.com\/2022-02-21-Abbotts-CardioMEMS-TM-HF-System-Receives-FDA-Approval-to-Support-Patients-Battling-Earlier-Stage-Heart-Failure<\/a><\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA), aprob\u00f3 una indicaci\u00f3n expandida para el sistema de monitoreo remoto CardioMEMS de Abbott. En febrero, la compa\u00f1\u00eda farmac\u00e9utica Abbott, anunci\u00f3 que la FDA, otorg\u00f3 la aprobaci\u00f3n al sistema CardioMEMS, que tiene como objetivo apoyar en el cuidado de personas que viven con insuficiencia cardiaca. Este sistema consiste en un sensor que alerta tempranamente a m\u00e9dicos sobre la condici\u00f3n de salud del paciente y la posibilidad de que la insuficiencia cardiaca empeore. Abbott explic\u00f3 en un comunicado que m\u00e1s de 6.2 millones de estadounidenses viven con insuficiencia cardiaca, cifra que se duplicar\u00eda para el 2030. En este sentido, los sistemas de monitoreo remoto pueden mejorar la atenci\u00f3n hacia los pacientes y hacer que los especialistas act\u00faen de manera m\u00e1s r\u00e1pida para evitar complicaciones. \u201cEl sensor CardioMEMS es un dispositivo del tama\u00f1o de un clip que, una vez colocado en la arteria pulmonar durante un procedimiento m\u00ednimamente invasivo, monitorea los cambios de presi\u00f3n que indican un empeoramiento de la insuficiencia card\u00edaca\u201d, explica la compa\u00f1\u00eda. De esta forma el sensor es capaz de transmitir de forma inal\u00e1mbrica informaci\u00f3n sobre lecturas diarias de presi\u00f3n al equipo cl\u00ednico del paciente, permitiendo que los m\u00e9dicos realicen cambios en la terapia para controlar la progresi\u00f3n de la enfermedad a una etapa posterior y m\u00e1s grave. De igual forma, el sistema permite que los pacientes tomen el control de su enfermedad desde donde se encuentren. Adem\u00e1s, este tipo de sistemas de monitoreo remoto han demostrado en pruebas cl\u00ednicas que son capaces de reducir hospitalizaciones de pacientes en etapas avanzadas de enfermedades cardiacas. De hecho, el sistema CardioMEMS fue sometido a un ensayo cl\u00ednico en el cual participaron 3 mil 600 pacientes. “CardioMEMS demostr\u00f3 una reducci\u00f3n significativa del 19 % en el criterio de valoraci\u00f3n compuesto del estudio y una reducci\u00f3n del 28 % en hospitalizaciones por insuficiencia cardiaca”, explica Abbott. BIBLIOGRAF\u00cdA ABBOTT https:\/\/abbott.mediaroom.com\/2022-02-21-Abbotts-CardioMEMS-TM-HF-System-Receives-FDA-Approval-to-Support-Patients-Battling-Earlier-Stage-Heart-Failure<\/p>","protected":false},"author":1,"featured_media":24568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[156,3393,160],"tags":[145],"class_list":["post-24566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-big-data","category-inteligencia-artificial-y-ciencia","category-noticias","tag-noticias"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/24566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/comments?post=24566"}],"version-history":[{"count":0,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/posts\/24566\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media\/24568"}],"wp:attachment":[{"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/media?parent=24566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/categories?post=24566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/saluddigital.com\/en\/wp-json\/wp\/v2\/tags?post=24566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}